YPEL2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P09265(YPEL2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09265(YPEL2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The YPEL2 antibody is a tool used to detect YPEL2 (Yippee-like 2), a protein belonging to the evolutionarily conserved YPEL family implicated in cellular senescence and cell cycle regulation. YPEL2. also known as Family with Sequence Similarity 132 Member A (FAM132A), shares structural homology with other YPEL proteins, including an N-terminal domain and five tandem TPR (tetratricopeptide repeat) motifs, which mediate protein-protein interactions. Studies suggest YPEL2 acts as a growth suppressor by inhibiting cell proliferation, potentially through interactions with p53 and retinoblastoma (Rb) pathways. Its expression is downregulated in certain cancers, such as breast and liver cancer, hinting at tumor-suppressive roles.

YPEL2 antibodies, typically rabbit or mouse monoclonal/polyclonal variants, are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study YPEL2 expression patterns, subcellular localization (primarily cytoplasmic), and dysregulation in diseases. Commercial antibodies are available from suppliers like Sigma-Aldrich, Abcam, and Santa Cruz Biotechnology. Research applications focus on understanding YPEL2's role in senescence, cancer progression, and developmental biology. However, variability in antibody specificity and validation across studies necessitates careful experimental optimization. Emerging interest in YPEL2 as a biomarker or therapeutic target underscores the antibody's importance in both basic and translational research.